Pharming Group Stock Forecast, Price & News

0.00 (0.00 %)
(As of 07/30/2021 09:30 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume55,300 shs
Average Volume5,325 shs
Market Capitalization$719.76 million
P/E Ratio23.00
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PHGUF News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

Pharming Group logo

About Pharming Group

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.30 out of 5 stars

Medical Sector

1237th out of 2,220 stocks

Tobacco Products Industry

5th out of 8 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

What stocks does MarketBeat like better than Pharming Group?

Wall Street analysts have given Pharming Group a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pharming Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pharming Group?

Pharming Group saw a drop in short interest in July. As of July 15th, there was short interest totaling 12,166,700 shares, a drop of 37.2% from the June 30th total of 19,367,700 shares. Based on an average daily trading volume, of 4,000 shares, the short-interest ratio is presently 3,041.7 days.
View Pharming Group's Short Interest

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) posted its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.01. Pharming Group had a net margin of 18.47% and a trailing twelve-month return on equity of 22.51%.
View Pharming Group's earnings history

How has Pharming Group's stock been impacted by Coronavirus (COVID-19)?

Pharming Group's stock was trading at $1.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PHGUF shares have decreased by 14.8% and is now trading at $1.15.
View which stocks have been most impacted by COVID-19

Who are Pharming Group's key executives?

Pharming Group's management team includes the following people:
  • Dr. Sijmen de Vries M.B.A., M.D., MBA, CEO & Exec. Director (Age 62, Pay $1.24M)
  • Dr. Bruno M. L. Giannetti, Consultant (Age 69, Pay $747.21k)
  • Mr. Jeroen Wakkerman, Chief Financial Officer (Age 52)
  • Ms. Mireille Sanders M.Sc., Chief Operations Officer (Age 53)
  • Susanne Embleton, Investor Relations Mang.
  • Mr. Ruud Van Outersterp, Chief Ethics & Compliance Officer
  • Mr. Anurag Relan, Chief Medical Officer (Age 49)
  • Mr. Paul Th. Jansse, VP & Head of Non-US Commercial Operations (Age 52)
  • Mr. Stephen Toor, Chief Commercial Officer & GM of Americas (Age 50)

Who are some of Pharming Group's key competitors?

What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $1.15.

How much money does Pharming Group make?

Pharming Group has a market capitalization of $719.76 million and generates $212.10 million in revenue each year. The biotechnology company earns $37.74 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Pharming Group have?

Pharming Group employs 262 workers across the globe.

What is Pharming Group's official website?

The official website for Pharming Group is www.pharming.com.

Where are Pharming Group's headquarters?

Pharming Group is headquartered at Darwinweg 24, Leiden P7, 2333 CR.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at 31-0-71-524-7400 or via email at [email protected]

This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.